Wedbush Boosts Oruka Therapeutics (NASDAQ:ORKA) Price Target to $85.00

Oruka Therapeutics (NASDAQ:ORKA) had its target price lifted by Wedbush from $45.00 to $85.00 in a report issued on Wednesday, Marketbeat Ratings reports. The firm presently has an “outperform” rating on the stock. Wedbush’s price target would suggest a potential upside of 26.73% from the stock’s current price.

Several other brokerages have also weighed in on ORKA. Guggenheim reissued a “buy” rating and set a $125.00 price objective on shares of Oruka Therapeutics in a report on Monday. BTIG Research raised their price target on Oruka Therapeutics from $73.00 to $78.00 and gave the stock a “buy” rating in a report on Monday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Oruka Therapeutics in a report on Thursday, January 22nd. Piper Sandler assumed coverage on Oruka Therapeutics in a report on Thursday, December 18th. They issued an “overweight” rating and a $75.00 price target for the company. Finally, Stifel Nicolaus raised their price target on Oruka Therapeutics from $47.00 to $72.00 and gave the stock a “buy” rating in a report on Friday, March 13th. Ten investment analysts have rated the stock with a Buy rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $78.90.

Oruka Therapeutics Trading Up 2.3%

Shares of ORKA opened at $67.07 on Wednesday. The company has a market capitalization of $3.32 billion, a price-to-earnings ratio of -36.06 and a beta of -0.54. The stock has a 50 day moving average of $42.08 and a 200 day moving average of $33.46. Oruka Therapeutics has a 12 month low of $8.36 and a 12 month high of $67.94.

Oruka Therapeutics (NASDAQ:ORKA) last issued its quarterly earnings results on Thursday, March 12th. The company reported ($0.45) EPS for the quarter, beating analysts’ consensus estimates of ($0.61) by $0.16. As a group, equities research analysts predict that Oruka Therapeutics will post -3.41 earnings per share for the current year.

Insider Activity

In other Oruka Therapeutics news, insider Joana Goncalves sold 7,641 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, March 16th. The stock was sold at an average price of $40.91, for a total transaction of $312,593.31. Following the sale, the insider directly owned 33,377 shares of the company’s stock, valued at approximately $1,365,453.07. The trade was a 18.63% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Lawrence Otto Klein sold 1,729 shares of Oruka Therapeutics stock in a transaction that occurred on Monday, March 16th. The shares were sold at an average price of $41.30, for a total value of $71,407.70. Following the sale, the chief executive officer directly owned 927,309 shares in the company, valued at approximately $38,297,861.70. The trade was a 0.19% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 23,765 shares of company stock worth $1,089,745. Company insiders own 24.69% of the company’s stock.

Institutional Trading of Oruka Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Royal Bank of Canada boosted its position in shares of Oruka Therapeutics by 47.2% in the 4th quarter. Royal Bank of Canada now owns 1,139 shares of the company’s stock worth $34,000 after purchasing an additional 365 shares in the last quarter. Kennedy Capital Management LLC boosted its position in shares of Oruka Therapeutics by 0.9% in the 4th quarter. Kennedy Capital Management LLC now owns 48,686 shares of the company’s stock worth $1,476,000 after purchasing an additional 420 shares in the last quarter. Russell Investments Group Ltd. boosted its position in shares of Oruka Therapeutics by 35.0% in the 4th quarter. Russell Investments Group Ltd. now owns 3,041 shares of the company’s stock worth $92,000 after purchasing an additional 788 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its position in shares of Oruka Therapeutics by 62.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,352 shares of the company’s stock worth $71,000 after purchasing an additional 904 shares in the last quarter. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Oruka Therapeutics in the 4th quarter worth approximately $37,000. 56.44% of the stock is owned by institutional investors.

Key Oruka Therapeutics News

Here are the key news stories impacting Oruka Therapeutics this week:

• Positive Sentiment: Wedbush raised its price target to $85 and assigned an “outperform” rating — a significant bullish signal that increases upside expectations for ORKA. Wedbush raises ORKA target
• Positive Sentiment: BTIG boosted its price target to $78, adding to the momentum from other firms raising targets and supporting buying interest. BTIG raises ORKA target to $78
• Positive Sentiment: HC Wainwright reiterated a “Buy” rating with a $70 target and published multi‑quarter and FY2026–FY2027 EPS forecasts, signaling continued analyst conviction that helps justify higher valuations. HC Wainwright coverage
• Positive Sentiment: Market surveys show ORKA with an average analyst rating of “Moderate Buy” and recent headlines note the stock hit a new 12‑month high after upgrades — these consensus signals support short‑term investor demand. Average rating: Moderate Buy New 12‑month high after upgrade
• Neutral Sentiment: Insider Joana Goncalves sold 7,000 shares under a pre‑arranged Rule 10b5‑1 plan (disclosed on SEC Form 4); because the sale was planned and disclosed, it’s less likely to signal new negative information but can add short‑term supply. SEC Form 4
• Negative Sentiment: Consensus and firm forecasts confirm ongoing multi‑year losses (consensus FY current year ≈ -$3.41 EPS; HC Wainwright FY2027 -$3.55), meaning valuation depends on future clinical/commercial milestones (ONCT‑01) and could limit longer‑term multiple expansion.

Oruka Therapeutics Company Profile

Oruka Therapeutics, Inc is a clinical‐stage biopharmaceutical company focused on the development of novel peptide‐based therapies for oncology. The company’s proprietary stapled peptide platform is designed to selectively disrupt intracellular protein–protein interactions that drive tumor growth and immune evasion. By combining the specificity of biologics with the cell‐permeability of small molecules, Oruka aims to target cancer pathways that have been historically considered “undruggable.”

The company’s lead candidate, ONCT-01, is currently in Phase 1 clinical trials for patients with advanced solid tumors, assessing safety, tolerability and preliminary efficacy.